How Scottish scientists are developing Artificial Intelligence for assessing Mesothelioma

Scientists in Scotland have developed a prototype imaging system using artificial intelligence that has proven effective with malignant mesothelioma, potentially revolutionising the way patients will be treated in the future.

The pilot program could spark much-needed advances in diagnostics and therapeutics.

Dr. Kevin Blythe, professor of respiratory medicine at University of Glasgow and respiratory physician at Queen Elizabeth University Hospital, told The Mesothelioma Centre;

“Mesothelioma is such a complex, incredibly difficult disease. This could be a very important step toward helping patients in the future.

In itself, artificial intelligence can’t change treatment, but it will help make better decisions with drug therapies.”

The University of Glasgow and Canon Medical Research Europe worked together in developing the novel technology built around artificial intelligence, or AI. The computer software can detect and measure cancer cells more effectively than traditional imaging.

It could be used to more accurately – and quickly – assess a mesothelioma patient’s immediate response to drug treatments such as chemotherapy and immunotherapy. 

Read more about how AI can support personalised treatments at